Overview

TB-500 is a synthetic heptapeptide corresponding to the N-acetylated active fragment (amino acids 17–23) of the endogenous 43-amino acid signaling protein thymosin beta-4. First isolated from thymus tissue in the 1960s, thymosin beta-4 is one of the most abundant G-actin sequestering molecules in mammalian cells. The TB-500 fragment retains the key LKKTET sequence responsible for much of the biological activity while offering improved bioavailability.

Mechanism of Action

TB-500's primary mechanism involves high-affinity binding to monomeric G-actin (Kd ~0.5-0.7 μM), sequestering it and preventing polymerization into F-actin filaments. This enables rapid cytoskeletal remodeling critical for cell migration and wound closure. Additional mechanisms include VEGF mRNA upregulation (2.5-3.8 fold), enhanced endothelial cell migration and angiogenesis, NF-κB pathway inhibition reducing pro-inflammatory cytokines (TNF-α, IL-1β, IL-6 by 40-60%), stem cell mobilization via the SDF-1α/CXCR4 axis, and modulation of extracellular matrix through MMP expression regulation.

Potential Benefits

  • Accelerated wound closure rates 40-55% faster than controls in diabetic models
  • Reduced inflammation through NF-κB inhibition and cytokine modulation
  • Improved muscle flexibility and reduced scar formation
  • Cardiac protection with ejection fraction improvements of 15-25% post-MI in animal models
  • Enhanced re-epithelialization and improved tissue quality
  • Stem cell mobilization to sites of injury
  • Corneal, dermal, and cardiac tissue repair support

Dosage Protocols

The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.

Typical Range2-5 mg/week
Beginner2 mg/week
Intermediate2.5-4 mg/week
Advanced5-7 mg/week
Cycle Duration4-8 weeks loading, then maintenance
Cycle Off4-8 weeks

Often used in a loading phase (2x/week) for 4 weeks followed by a maintenance phase (once/week). Doses are in mg, not mcg, due to the larger peptide size.

Routes of Administration

Subcutaneous Injection High

Standard route; well tolerated; inject into abdominal fat or near injury site

Intramuscular Injection High

Alternative to subcutaneous; may achieve faster onset for deep muscle injuries

Stacking Protocols

Popular research stacks involving TB-500:

Ultimate Recovery Stack

Synergistic tissue repair across all tissue types

The most popular peptide combination; TB-500 handles systemic inflammation and actin remodeling while BPC-157 provides targeted cytoprotection and vascular repair.

Cardiac Protection Stack

Cardioprotection and mitochondrial function support

TB-500's proven cardioprotective effects in post-MI models combined with mitochondrial-targeting peptides.

Athletic Performance Stack

Injury prevention, muscle growth, and recovery optimization

TB-500 supports connective tissue health while GH axis peptides drive anabolism and recovery.

Reconstitution

Typical Vial Size5mg, 10mg
BAC Water1-2ml per 5mg vial
StorageRefrigerate at 2-8°C after reconstitution
Shelf Life28-30 days refrigerated

Need exact syringe measurements?

Amino Acid Sequence

Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES (full Tβ4); Active fragment: Ac-LKKTETQ

Side Effects & Safety

  • Potential tumor growth promotion (theoretical concern with angiogenic activity)
  • Flu-like symptoms reported anecdotally
  • Lethargy immediately post-injection in some cases
  • Long-term human safety data lacking

Synergistic Compounds

The following compounds have been studied alongside TB-500 for potential complementary or synergistic effects:

Learn More

References & Further Reading

  • [object Object]
  • [object Object]
  • [object Object]